• Share:

Publications 1999

Can't find the PDF you are looking for? Email Jessica Kohn for assistance.

 

Publications: 1999

Hsu J-Y, Hsu M-Y, Sorger T, Herlyn M, Levine EM:Heparin/ECGS regulates matrix gene expression and prolongs life span of vascular smooth muscle cells through modulations of IL-1. In Vitro, 35: 1-8, 1999.

Sauter ER, Nesbit M, Watson JC, Seykora JP, Klein-Szanto A, Herlyn M: Vascular endothelial growth factor expression is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck. Clin. Cancer Res, 5: 775-782, 1999.   PDF

Moretti S, Pinzi C, Spallanzani A, Berti E, Chiarugi A, Mazzoli S, Fabiani C, Vallecchi C, Herlyn M: Immunohistochemical evidence of cytokine networks during tumor progression of human melanocytic lesions. Int. J Cancer, 84: 160-168, 1999.   PDF

Liechty, KW, Nesbit, M, Herlyn M, Radu, A, Adzick, NS, Crombleholme, TM: Adenoviral mediated overexpression of platelet-derived growth factor-B corrects ischemic impaired wound healing. J. Invest. Dermatol, 113: 375-383, 1999.  

Nesbit M, Nesbit HKE, Bennet J, Andl T, Hsu M-Y, DeJesus E, McBrian M, Gupta AR, Eck SL, Herlyn M: Basic fibroblast growth factor induces a transformed phenotype in normal human fibroblasts. Oncogene, 18: 6469-6476, 1999.   PDF

Van Belle PA, Elenitsas R, Satyamoorthy K, Wolfe JT Guerry, IV, D, Schuchter, L, Van Belle TJ, Albelda S, Tahin, P, Herlyn M, Elder DE: Progression-related expression of ß3 integrin in melanomas and nevi. Hum. Pathol. 30: 562-567, 1999.

Prabhu, NS, Somasundaram, K, Tian, H, Enders, GH, Satyamoorthy, K, Herlyn, M, El-Deiry, W: The administration schedule of cyclin-dependent kinase inhibitor gene therapy and etoposide chemotherapy is a major determinant of cytotoxicity. Int. J. Oncol. 15: 209-216, 1999.

Easty, DJ, Hill, SP, Hsu, M-Y, Fallowfield, ME, Florenes, VA, Herlyn, M, Bennet, DC: Upregulation of EPHRIN-A1 during melanoma progression. Int. J. Cancer 84: 494-501 1999.   PDF

Mitra, J, Somasundaram, K, El-Deiry, WS, Satyamoorthy, S, Herlyn, M, Enders, GH: p21 WAF1/CIP1 is an effector for p16INJ4a/CDKN2A. Mol. Cell. Biol,, 19: 3916-3928, 1999.

Krasilnikov, M, Adler, V, Fuchs, SY, Dong, Z, Haimovitz-Friedman, A, Herlyn, M, Ronai, Z: Contribution of phoshatidylinositol 3-kinase to radiation resistance in human melanoma cells. Mol. Carcinogenesis, 24: 64-69, 1999.

Sauter ER, Nesbit M, Litwin S, Klein-Szanto A, Cheffetz S, Herlyn M: Antisense cyclin D1 causes decreased proliferation, increases apoptosis and tumor shrinkage in human squamous cell carcinomas. Cancer Res. 59: 4876-4881, 1999.    PDF

Ge K, DuHadaway, J, Herlyn, M, Rodeck, U, Prendergast GC: Novel mechanism for elimination of a tumor suppressor: Aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma. Proc. Natl. Acad. Sci., USA, 96: 9689-9694, 1999.

Oka M, Berking, C, Nesbit M, Satyamoorthy K, Schaider, H, Murphy GF, Ichihashi M, Sauter, ER, Herlyn M: IL-8 overexpression is present in pyoderma gangrenosum ulcers and leads to ulcer formation in human skin xenografts. Lab. Invest, 80: 595-604, 1999.

Hsu M-Y, Elder DE, Herlyn M: Melanoma: The Wistar (WM) melanoma cell lines, In: Human cell culture, Vol. 3, ed. by J.R.W. Masters and B. Palsson, Kluwer Acad. Publ., London, 259-274, 1999.

Herlyn, M: Endothelial cells as targets for tumor therapy. Editorial. J Immunotherapy: 22, 185, 1999.

Satyamoorthy, K, Meier, F, Hsu, M-Y, Berking, C, Herlyn, M: Human xenografts, human skin and skin reconstructs for studies in melanoma development and progression. Cancer Met. Rev. 18: 401-405, 1999.